Hepatitis C virus recurrence after liver transplantation: A 10-year evaluation

Table 3 Characteristics of patients divided by groups

Group	A	B	C	D	E	χ2/Kruskall Wallis
	SVR	NR	Mild recurrence	Too sick	Comorbidity
n	63	87	73	35	100
Gender (M/F)	47/16	73/14	63/10	20/15	78/22	P = 0.007
Age at LT (yr, mean ± SD)	52 ± 8	52 ± 9	53 ± 8	52 ± 9	51 ± 9	P = NS
Donor age (yr, mean ± SD)	49 ± 17	56 ± 15	48 ± 17	59 ± 15	55 ± 17	P = 0.001
HCV genotype						P = NS
1	37	60	45	16	44
2	7	6	9	3	13
3	9	13	6	5	14
4	8	5	7	1	10
Immunosuppression	48	55	54	24	83	P = NS
Cyclosporine	14	31	16	10	13
Tacrolimus	1	1	3	1	4
Other regimens
Time between treatment start and LT [mo, median (min-max)]	20 (1-148)	16 (1-117)				P = NS
Treatment Length [mo, median (min-max)]	11 (1-61)	6 (1-63)				P = 0.010

SVR: Sustained virological response; NR: Non-response; HCV: Hepatitis C virus; NS: Not significant; LT: Liver transplantation.